Response to insulin degludec and insulin glargine 300 U/mL: Which of these two insulins causes less hypoglycemia?

Response to insulin degludec and insulin glargine 300 U/mL: Which of these two insulins causes less hypoglycemia?

Bibliographic Details
Main Author:	Mizuho Yamabe
Format:	Article
Language:	English
Published:	Wiley 2019-11-01
Series:	Journal of Diabetes Investigation
Online Access:	https://doi.org/10.1111/jdi.13145

Similar Items

Insulin degludec and insulin glargine 300 U/mL: Which of these two insulins causes less hypoglycemia?
by: Silvio Buscemi, et al.
Published: (2019-11-01)

Comparison of insulin glargine 300 U/mL and insulin degludec using flash glucose monitoring: A randomized cross‐over study
by: Mizuho Yamabe, et al.
Published: (2019-03-01)

Day‐to‐day variability of porcine lente, insulin glargine 300 U/mL and insulin degludec in diabetic dogs
by: Michelle Miller, et al.
Published: (2021-09-01)

Conversion from insulin glargine U-100 to insulin glargine U-300 or insulin degludec and the impact on dosage requirements
by: Scott M. Pearson, et al.
Published: (2018-04-01)

Comparison of the efficacy and safety of insulin degludec/aspart (twice‐daily injections), insulin glargine 300 U/mL, and insulin glulisine (basal–bolus therapy)
by: Yuji Kawaguchi, et al.
Published: (2019-11-01)

Nocturnal Glycemic Control with New Insulin Glargine 300 U/mL
by: Neng Chun Yu
Published: (2019-01-01)

Insulin glargine 300 U/mL for basal insulin therapy in type 1 and type 2 diabetes mellitus
by: Lau IT, et al.
Published: (2017-06-01)

A practical guide to the interpretation of PK/PD profiles of longer-acting analogue insulins. Part two: Insulin degludec vs. insulin glargine U300
by: Oppel B.W. Greeff, et al.
Published: (2018-08-01)

Insulin glargine 300 U/ml in the management of diabetes: clinical utility and patient perspectives
by: de Galan BE
Published: (2016-10-01)

Glargine and degludec: Solution behaviour of higher dose synthetic insulins
by: Gary G. Adams, et al.
Published: (2017-08-01)

Efficacy and safety of insulin glargine 300 U/mL vs insulin degludec in patients with type 2 diabetes: A randomized, open‐label, cross‐over study using continuous glucose monitoring profiles
by: Yuji Kawaguchi, et al.
Published: (2019-03-01)

Efficacy and Safety of Insulin Glargine 300 U/mL versus 100 U/mL in Diabetes Mellitus: A Comprehensive Review of the Literature
by: Hernando Vargas-Uricoechea
Published: (2018-01-01)

Clinical experience in using long-acting human insulin Glargine 300 U/ml in the practice of an endocrinologist
by: O. A. Guseva, et al.
Published: (2018-04-01)

Insulin degludec
by: Vishakha V Jain, et al.
Published: (2013-01-01)

The effect of concomitant DPPIVi use on glycaemic control and hypoglycaemia with insulin glargine 300 U/mL (Gla-300) versus insulin glargine 100 U/mL (Gla-100) in people with type 2 diabetes: A patient-level meta-analysis of EDITION 2 and 3.
by: Jean-François Yale, et al.
Published: (2018-01-01)

Cost-effectiveness of insulin degludec versus insulin glargine U100 in adults with type 1 and type 2 diabetes mellitus in Bulgaria
by: Monika Russel-Szymczyk, et al.
Published: (2019-12-01)

Insulin degludec and insulin degludec/insulin aspart in Ramadan: A single center experience
by: Sanjay Kalra
Published: (2016-01-01)

Efficacy and Safety of Insulin Degludec versus Insulin Glargine: A Systematic Review and Meta-Analysis of Fifteen Clinical Trials
by: Wei Liu, et al.
Published: (2018-01-01)

Efficacy and Safety of Once-Daily Insulin Degludec/Insulin Aspart versus Insulin Glargine (U100) for 52 Weeks in Insulin-Naïve Patients with Type 2 Diabetes: A Randomized Controlled Trial.
by: Ajay Kumar, et al.
Published: (2016-01-01)

The effectiveness of insulin glargine 300 U/mL among type 2 diabetes patients: Analysis of a real‐world data in Israel
by: Cheli Melzer Cohen, et al.
Published: (2020-07-01)

Degludec insulin: A novel basal insulin
by: Sanjay Kalra, et al.
Published: (2011-01-01)

Efficacy and safety of switching to insulin glargine 300 U/mL from 100 U/mL in Japanese patients with type 2 diabetes: A 12-month retrospective analysis
by: Kazutoshi Sugiyama, et al.
Published: (2019-02-01)

rDNA insulin glargine U300 – a critical appraisal
by: Wang F, et al.
Published: (2016-12-01)

Switching from Neutral Protamine Hagedorn Insulin to Insulin Glargine 300 U/mL Improves Glycaemic Control and Reduces Hypoglycaemia Risk: Results of a Multicentre, Prospective, Observational Study
by: B. Wolnik, et al.
Published: (2020-01-01)

Real-World Effectiveness of Insulin Glargine 300 Initiation in Switzerland
by: Thomann R, et al.
Published: (2020-07-01)

Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16)
by: Andersen, A., et al.
Published: (2019)

Hypoglycaemia and treatment patterns among insulin‐treated patients with type 2 diabetes who switched to insulin glargine 300 units/mL versus other basal insulin in a real‐world setting
by: Fang L. Zhou, et al.
Published: (2019-07-01)

On the safety of insulin Glargine
by: Ivan Ivanovich Dedov, et al.
Published: (2009-09-01)

The differences between insulin glargine U300 and insulin degludec U100 in impact on the glycaemic variability, arterial stiffness and the lipid profiles in insulin naïve patients suffering from type two diabetes mellitus – outcomes from cross‐over open-label randomized trial
by: Pavle Vrebalov Cindro, et al.
Published: (2021-04-01)

Insulin Degludec, The New Generation Basal Insulin or Just another Basal Insulin?
by: Sami N. Nasrallah, et al.
Published: (2012-04-01)

Insulin Degludec, The New Generation Basal Insulin or Just another Basal Insulin?
by: Sami N. Nasrallah, et al.
Published: (2012-01-01)

Is insulin degludec a more effective treatment for patients using high doses of insulin glargine but not attaining euglycemia? Some case reports from India
by: Sinha B, et al.
Published: (2014-06-01)

Insulin/carbohydrates ratio during the first 6‐month therapy with insulin degludec in a paediatric population with type 1 diabetes previously treated with insulin glargine. An observational longitudinal study
by: Stefano Tumini, et al.
Published: (2020-04-01)

Pediatric diabetes: Potential for insulin degludec
by: Sanjay Kalra, et al.
Published: (2014-01-01)

Insulin degludec/insulin aspart is the first co-formulation of basal and prandial insulin analogues
by: Ivan Ivanovich Dedov, et al.
Published: (2014-12-01)

Insulin glargine: A long acting insulin analog
by: Chakkarwar P, et al.
Published: (2005-01-01)

Insulin Glargine and Insulin Aspart Overdose With Pharmacokinetic Analysis
by: Christian C.K. Kim, MD, et al.
Published: (2016-01-01)

Lantus (Insulin Glargin): new insulin on Russian market
by: Editorial team Diabetes Mellitus
Published: (2003-03-01)

Insulin degludec is a new ultra-long-acting insulin analogue
by: Ivan Ivanovich Dedov, et al.
Published: (2014-06-01)

Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14
by: Richard E. Pratley, et al.
Published: (2019-11-01)